The therapeutic effect in obese subjects of EA is the alleviation of obesity-induced inflammation through suppressing HIF-1α signaling and restraining the NF-κB signaling pathway (51). Here, HIF1A is linked to obesity due to melanocortin 4 receptor deficiency.